[논문]Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma

Lee, Min Young; Park, Chan-Jeoung; Cho, Young-Uk; You, Eunkyoung; Jang, Seongsoo; Seo, Eul Ju; Lee, Jung-Hee; Yoon, Dok Hyun; Suh, Cheolwon

doi:10.3343/alm.2021.41.3.259

[국내논문] Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma 원문보기

Annals of laboratory medicine, v.41 no.3, 2021년, pp.259 - 267

Lee, Min Young (Department of Laboratory Medicine, Kyung Hee University School of Medicine and Kyung Hee University Hospital, Gangdong, Seoul, Korea) , Park, Chan-Jeoung (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Cho, Young-Uk (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , You, Eunkyoung (Department of Laboratory Medicine, Inje University College of Medicine, Busan Baik Hospital, Busan, Korea) , Jang, Seongsoo (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Seo, Eul Ju (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Lee, Jung-Hee (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Yoon, Dok Hyun (Department of Oncology, As) , Suh, Cheolwon

Abstract ▼ AI-Helper

BackgroundPlasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM.MethodsA total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry.ResultsAt diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P<0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P=0.001) and after complete remission following chemotherapy (P=0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy.ConclusionsPD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.

주제어

참고문헌 (24)

1 Patel SP Kurzrock R 2015 PD-L1 expression as a predictive biomarker in cancer immunotherapy Mol Cancer Ther 14 847 56 10.1158/1535-7163.MCT-14-0983 25695955

상세보기
2 Lesokhin AM Ansell SM Armand P Scott EC Halwani A Gutierrez M 2016 Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study J Clin Oncol 34 2698 704 10.1200/JCO.2015.65.9789 27269947

상세보기
3 Usmani SZ Schjesvold F Rocafiguera AO Karlin L Rifkin RM Yimer HA 2018 A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): Keynote-185 J Clin Oncol 36 8010 10.1200/JCO.2018.36.15_suppl.8010

상세보기
4 Mateos MV Blacklock H Schjesvold F Rocafiguera AO Simpson D George A 2018 A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Keynote-183 J Clin Oncol 36 8021 10.1200/JCO.2018.36.15_suppl.8021

상세보기
5 Palumbo A Avet-Loiseau H Oliva S Lokhorst HM Goldschmidt H Rosino L 2015 Revised international staging system for multiple myeloma: a report from International Myeloma Working Group J Clin Oncol 33 2863 9 10.1200/JCO.2015.61.2267 26240224

상세보기
6 Mikhael JR Dingli D Roy V Reeder CB Buadi FK Hayman SR 2013 Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 Mayo Clin Proc 88 360 76 10.1016/j.mayocp.2013.01.019 23541011

상세보기
7 Health Insurance Review & Assessment Service Healthcare big data hub http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do Updated on Jan 2020
8 Kumar SK Rajkumar SV Dispenzieri A Lacy MQ Hayman SR Buadi FK 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 20 10.1182/blood-2007-10-116129 17975015

상세보기
9 Lee HY Park CJ Ahn A Lee MY Cho YU Jang S Seo EJ Lee KH Lee JH Lee HY 2019 Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma Ann Lab Med 39 496 8 10.3343/alm.2019.39.5.496 31037870

상세보기
10 Paiva B Azpilikueta A Puig N Ocio EM Sharma R Oyajobi BO 2015 PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma Leukemia 29 2110 3 10.1038/leu.2015.79 25778100

상세보기
11 Stathopoulou C Gangaplara A Mallett G Flomerfelt FA Liniany LP Knight D 2018 PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells Immunity 49 247 63 e7 10.1016/j.immuni.2018.05.006 30054205

상세보기
12 Amarnath S Costanzo CM Mariotti J Ullman JL Telford WG Kapoor V 2010 Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1 PLoS Biol 8 e1000302 10.1371/journal.pbio.1000302 20126379

상세보기
13 Amarnath S Chen H Foley JE Costanzo CM Sennesh JD Solomon MA 2011 Host-based Th2 cell therapy for prolongation of cardiac allograft viability PLoS One 6 e18885 10.1371/journal.pone.0018885 21559526

상세보기
14 Muthu Raja KR Rihova L Zahradova L Klincova M Penka M Hajek R 2012 Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma PLoS One 7 e47077 10.1371/journal.pone.0047077 23071717

상세보기
15 Karnell FG Lin D Motley S Duhen T Lim N Campbell DJ 2017 Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation Clin Exp Immunol 189 268 78 10.1111/cei.12985 28498568

상세보기
16 Arruda LCM de Azevedo JTC de Oliveira GLV Scortegagna GT Rodrigues ES Palma PVB 2016 Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation Clin Immunol 169 47 57 10.1016/j.clim.2016.06.005 27318116

상세보기
17 Simonetta F Pradier A Bosshard C Masouridi-Levrat S Dantin C Koutsi A 2019 Dynamics of expression of programmed cell death protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation Front Immunol 10 1034 10.3389/fimmu.2019.01034 31156625

상세보기
18 Merindol N Champagne MA Duval M Soudeyns H 2011 CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse Blood 118 4480 8 10.1182/blood-2011-04-349241 21813446

상세보기
19 Pawlyn C Morgan GJ 2017 Evolutionary biology of high-risk multiple myeloma Nat Rev Cancer 17 543 56 10.1038/nrc.2017.63 28835722

상세보기
20 Corrado C Raimondo S Chiesi A Ciccia F De Leo G Alessandro R 2013 Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications Int J Mol Sci 14 5338 66 10.3390/ijms14035338 23466882

상세보기
21 Roccaro AM Sacco A Maiso P Azab AK Tai YT Reagan M 2013 BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression J Clin Invest 123 1542 55 10.1172/JCI66517 23454749

상세보기
22 Raimondi L De Luca A Amodio N Manno M Raccosta S Taverna S 2015 Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation Oncotarget 6 13772 89 10.18632/oncotarget.3830 25944696

상세보기
23 Lemaire M Deleu S De Bruyne E Van Valckenborgh E Menu E Vanderkerken K 2011 The microenvironment and molecular biology of the multiple myeloma tumor Adv Cancer Res 110 19 42 10.1016/B978-0-12-386469-7.00002-5 21704227
24 Neri P Ren L Azab AK Brentnall M Gratton K Klimowicz AC 2011 Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion Blood 117 6202 13 10.1182/blood-2010-06-292243 21474670

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

[국내논문] Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (24)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트